ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Damaj, Gandhi ^a,b,c   Joris, Magalie ^a   Chandesris, Olivia ^b,d   Hanssens, Katia ^e   Soucie, Erinn ^e   Canioni, Danielle ^d   Kolb, Brigitte ^f   Durieu, Isabelle ^g   Gyan, Emanuel ^h   Livideanu, Cristina ⁱ   Chèze, Stephane ^j   Diouf, Momar ^a   Garidi, Reda ^k   Georgin Lavialle, Sophie ^l   Asnafi, Vahid ^d   Lhermitte, Ludovic ^d   Lavigne, Christian ^m   Launay, David ⁿ   Arock, Michel ^o,p   Lortholary, Olivier ^d   Dubreuil, Patrice ^e   Hermine, Olivier ^b,c,d   more..

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Institut Fédératif de Recherche 94   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k CENTRE HOSPITALIER   (France)

^l SORBONNE UNIVERSITÉ   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o Ecole Normale Superieure de Cachan   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; HEMOGLOBIN; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES; ASXL1 GENE; BONE DENSITY; CBL GENE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GENE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; KIT GENE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SKIN DEFECT; SPLENOMEGALY; SURVIVAL TIME; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS LYMPHOID WITH ASSOCIATED HEMATOLOGIC CLONAL NON MAST CELL DISEASE; SYSTEMIC MASTOCYTOSIS MYELOID WITH ASSOCIATED HEMATOLOGIC CLONAL NON MAST CELL DISEASE; TET2 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; DNA-BINDING PROTEINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MONOCYTES; MUTATION; NEUTROPENIA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-KIT; REPRESSOR PROTEINS; SURVIVAL ANALYSIS;

EID: 84896535727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085362     Document Type: Article

References (23)

1. Horny AC, Metcalfe DD, et al. (2008) Mastocytosis. In: Swerdlow S, Campo E, Lee Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: Press I, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon:53-63.
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603-25. (Pubitemid 32506768)
3. Horny HP, Valent P. (2001) Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25:543-51.
4. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, et al. (2009) Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23:900-4.
5. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, et al. (2012) Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 7:e43090.
6. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, et al. (2009) Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114:3769-72.
7. Soucie E HK, Mercher T, Georgin-Lavialle S, Damaj G, Chandesris MO, et al.(2012) In Aggressive Forms of Mastocytosis, TET2 Loss Cooperates with c-KITD816V to Transform Mast Cells. Blood 120: 4846-9.
8. Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, et al. (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One Apr 9:e1906.
9. Delhommeau F, Dupont S, Tonetti C, Masse A, Godin I, et al.(2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109:71-7. (Pubitemid 46053046)
10. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-301.
11. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, et al. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800.
12. Ambler G, Seaman S, Omar RZ. (2011) An evaluation of penalised survival methods for developing prognostic models with rare events. Stat Med 31:1150-61.
13. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345-68. (Pubitemid 19003322)
14. Horny HP, Sotlar K, Sperr WR, Valent P. (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57:604-8. (Pubitemid 38725760)
15. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, et al. (2010) Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 220:586-95.
16. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, et al. (2008) Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 3:e2266.
17. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12:599-612.
18. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343-5.
19. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. (2011) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29:1373-81.
20. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, et al. (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-11.
21. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, et al. (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-506.
22. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, et al. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079-89.
23. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, et al. (2012) Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 5:12.